The findings likely have implications for animal research far beyond the study of antidepressants.

Preliminary findings from a clinical trial of heavy drinkers suggest that the drug can weaken certain memories tied to the reward of imbibing, although the mechanisms aren’t fully clear.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

The facility, focused on finding treatments for mental health disorders, will be the first of its kind in the US.

The drug promotes and sustains brain cell connectivity in mice, reversing the effects of chronic stress.